NerPharMa and ICROM partner on highly potent drugs and ADC-payloads

This agreement outlines the sharing of technologies, know-how, facilities and workforce of the two companies

NerPharMa, a veteran CDMO with a specialisation in oncology small molecule drug manufacture and a member of NMS Group, announce a Partnership Agreement with ICROM srl, aiming for collaboration on commercial production of High Potent drugs and ADC-Payload.

This agreement outlines the sharing of technologies, know-how, facilities and workforce of the two companies to offer API development and formulated drug production services to third-party companies in increasingly strategic sectors of oncology and neurology.

“The structural growth of the API division is a key component in NerPharMa's strategic plan. In order to reach the highest potential of our facilities, we see the partnership with ICROM as an essential step to accelerate the process to offer our customers concrete and qualitatively high-tech solutions in a very short time”, said Angelo Colombo CEO of NerPharMa.”

“We are extremely excited about this partnership with a leading enterprise that has been operating in the sector with proven successes for many years” said Pierfrancesco Morosini, CEO of ICROM, “I am absolutely convinced that the synergy of the capabilities and potentials of the two companies will bring us mutually beneficial outcome, in this fierce global competition context.”

Featured Companies

Icrom SRL (more information, website)